2022-11-10

Camurus' Interim Report for third quarter 2022

Lab Work

Camurus' Interim Report for the third quarter, which was published today, showed that this was Camurus' financially best quarter to date.

Read the full press release on Camurus' website:

Camurus’ Interim Report Third Quarter 2022 - Camurus

Latest news

2018-12-07

Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence

Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company’s lead p…

Read more

2018-11-22

Camurus receives EU approval for Buvidal®

Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence. Buvidal® is the first…

Read more

2018-10-26

AF Bostäder has installed SWATAB's filter system

AF Bostäder in Lund will open two new laundry rooms at Vildanden, a student housing, where the students can wash wit…

Read more

2018-10-26

Camurus Interim Report January-September 2018

“Following the positive CHMP opinion for Buvidal®, we have ramped up our commercial activities and are ready for lau…

Read more

2018-07-20

Solo Rescue to spin-off from GRANULDISK

Sandberg Development has decided to spin-off and concentrate the business within the subsidiary GRANULDISK’s product…

Read more